source
- Replimune to resubmit melanoma therapy RP1 to FDA after two prior rejectionsReplimune announced on Friday that it will again submit its advanced melanoma candidate, RP1, to the U.S. Food and Drug Administration for review. The company says the filing follows new discussion…
- GSK and Ionis report functional cure in 20% of hepatitis B patients with bepirovirsen in early trialsGSK and Ionis disclosed results from two clinical studies of their RNA‑based injection, bepirovirsen, aimed at achieving a functional cure for chronic hepatitis B. In both trials about one‑fifth o…